v3.26.1
Cover - USD ($)
$ / shares in Units, $ in Millions
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Mar. 25, 2026
Jun. 30, 2025
Cover [Abstract]        
Document Type 10-K      
Amendment Flag false      
Document Annual Report true      
Document Transition Report false      
Document Period End Date Dec. 31, 2025      
Document Fiscal Period Focus FY      
Document Fiscal Year Focus 2025      
Current Fiscal Year End Date --12-31      
Entity File Number 001-41184      
Entity Registrant Name ZYVERSA THERAPEUTICS, INC.      
Entity Central Index Key 0001859007      
Entity Tax Identification Number 86-2685744      
Entity Incorporation, State or Country Code DE      
Entity Address, Address Line One 2436 N. Federal Highway      
Entity Address, Address Line Two Suite 466      
Entity Address, City or Town Lighthouse Point      
Entity Address, State or Province FL      
Entity Address, Postal Zip Code 33064      
City Area Code (754)      
Local Phone Number 231-1688      
Title of 12(b) Security Common Stock, $0.0001 par value per share      
Trading Symbol ZVSA      
Entity Well-known Seasoned Issuer No      
Entity Voluntary Filers No      
Entity Current Reporting Status Yes      
Entity Interactive Data Current Yes      
Entity Filer Category Non-accelerated Filer      
Entity Small Business true      
Entity Emerging Growth Company true      
Elected Not To Use the Extended Transition Period false      
Entity Shell Company false      
Entity Public Float       $ 3.3
Entity Common Stock, Shares Outstanding     8,095,921  
Document Financial Statement Error Correction [Flag] false      
Entity Listing, Par Value Per Share $ 0.0001      
Auditor Firm ID 199 688    
Auditor Opinion [Text Block] We have audited the accompanying consolidated balance sheet of ZyVersa Therapeutics, Inc. (the “Company”) as of December 31, 2025 the related consolidated statements of operations, changes in stockholders’ deficit, and cash flows for the year ended December 31, 2025, and the related notes (collectively referred to as the “financial statements”). In our opinion, based on our audit, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2025 and the results of its operations and its cash flows for the year ended December 31, 2025, in conformity with accounting principles generally accepted in the United States of America.      
Auditor Name CBIZ CPAs P.C. Marcum LLP    
Auditor Location New York, NY New York, NY